[{"date": "2025-08-04", "news": "IDEXX Labs reported Q2 2025 EPS of $3.63, beating forecasts by 10.33%, with revenue reaching $1.11B (+11% YoY). Stock surged 22.6% in pre-market trading. Full-year guidance was raised."}, {"date": "2025-08-14", "news": "Michael Erickson, EVP of Point of Care Diagnostics, sold 405 shares at $649.96 as part of routine portfolio management."}, {"date": "2025-08-12", "news": "Sharon Underberg, Executive VP and General Counsel, sold 5,450 shares at $444.66; Jonathan Mazelsky, CEO, bought 183 shares at $598.49, signaling leadership confidence."}, {"date": "2025-08-09", "news": "CEO Jonathan Mazelsky sold 29,260 shares at $564.13, likely related to tax or estate planning, while the company maintained strong operational performance."}]